Transforming ACL Reconstruction Surgery
With the QuadVantage Autograft System (Instruments and Procedures) your local orthopedic surgeon can provide a superior Quadriceps ACL Reconstruction experience – one that is less traumatic, less likely to fail and easier to recover from.
Amount Subscribed To Date : $891,375
Minimum Investment: $500 | Price per Share $2.50 | Non-Voting Preferred Shares,
5% Annual Dividend, Investment fees waived through 12/15/22


The Need
ACL Reconstruction - A Growing Market
As society at all ages moves to a more active lifestyle, the incidence of ACL injuries continues to grow – It is no longer an issue just for athletes. According to data from Transparency Market Research 2021, over 900,000 ACL reconstruction surgeries are expected to be performed in North America and Europe in 2023. Worldwide the number of ACL surgeries is approaching 2 Million per year.
The Problem
Issues with Current
Reconstruction Techniques
Mainstream ACL reconstruction techniques utilize Patellar, Hamstring or Allograft (cadaver) tendon grafts as replacements for the injured tendon. Key issues continue to plague patient’s that undergo these surgeries;
Trauma
Postoperative Pain, Swelling & Infection
use of narcotics
To Treat Pain
ugly scars
Evident Forever
LONG TERM ISSUES
Knee Pain, Graft Failure
The Solution
The QuadVantage Quadriceps Autograft System
Based on research conducted over several decades, it is believed that the Quadriceps tendon is superior to Patellar, Hamstring and Allograft alternatives.
The complexity of harvesting the Quadriceps tendon, however, has kept it out of the mainstream.
The Patented QuadVantage Quadriceps Autograft solution makes harvesting of the Quadriceps tendon easier; adding precision, eliminating guesswork and minimizing trauma to the knee – making the procedure locally accessible for ordinary patients at any age.


Precise procedure
Eliminates Guesswork Minimizes Trauma & Pain
Small Scar
Practically Disappears
A BETTER GRAFT
Quadriceps
American Made
Lower Cost per Case Vs Competition
recyclable
Stainless Steel
INVEST IN THE FUTURE
A Comprehensive Solution With Significant Advantages
QuadVantage will provide a full solution to measure, shape, harvest, extract and attach a high performance Quadriceps tendon graft tailored the individual patients needs at any age.
quadvantage
Terms of Offering
Company
QuadVantage Technology, Inc.
Description of Business
Advanced Medical Devices for ACL Reconstruction
Type of Shares
Series CF Non-Voting Preferred Stock , 5% Annual Dividend
Purchase Price of Security Offered
$2.50 per share
Minimum Investment Amount (per investor)
$500.00
Maximum Target Amount
$5.0 Million
TARGET OFFERING AMOUNT
$25,000
Establishes point at which the company can initiate the first close.
Deadline to Reach Target Offering Amount
April 23, 2023


In making an investment decision, Investors must rely on their own examination of the Company and the terms of the Offering, including the merits and risks involved. The Company has filed a Form C with the Securities and Exchange Commission in conjunction with its Offering that provides significant details on the Company, the Securities offered, and the risks involved in making an investment.
INVEST IN THE FUTURE
Why Invest in QuadVantage?
- Growing Market Known for High Returns*
- An opportunity to step in at a value inflection point ahead of the Company’s initial product launch in the United States
- Clinically Tested, Proven Products
- No long FDA Clinical Trial or Approval Process Left to Navigate
- Strong Intellectual Property Portfolio
- Highly Experienced and Invested Team
- A Made in America Mentality
Join The Discussion
Commentary that is abusive, hateful, or fraudulent will be removed.
FAQS
Frequently Asked Questions
QuadVantage will provide a full solution to measure, shape, harvest, extract and attach a high performance Quadriceps tendon graft tailored the individual patient’s needs at any age.
Historically, private companies could only raise capital from accredited investors, the wealthiest 2% of Americans. In 2016, four years after the landmark JOBS Act legislation was signed, Title III (aka Regulation CF) of the JOBS Act went into effect, allowing private early-stage companies, subject to specific regulations, to raise up to $5Million from all Americans. Reg CF allows companies to raise capital on-line from early adopters and the crowd (similar to a Kickstarter campaign) and receive equity in the start-ups they back. Refer to the information on our intermediary's site https://www.dealmaker.tech/content/regulation-cf-explained for more information.
Crowdfunding allows investors to support startups and early-growth companies that they are passionate about. This is different from helping a company raise money on Kickstarter. With Regulation CF Offerings, you aren’t buying products or merchandise. You are buying a piece of a company and helping it grow.
Investors other than accredited investors are limited in the amounts they are allowed to invest in all Regulation Crowdfunding offerings (on this site and elsewhere) over the course of a 12-month period: If either of an investor’s annual income or net worth is less than $107,000, then the investor’s investment limit is $2,200, or 5 percent of the greater of the investor’s annual income or net worth, whichever is greater. If both an investor’s annual income and net worth are $107,000 or higher, then the investor’s limit is 10 percent of the greater of their annual income or net worth, or $107,000 whichever is greater. Accredited investors are not limited in the amount they can invest.
The Company believes that the surgical complexity associated with harvesting the Quadriceps tendon has prevented it from becoming a widely performed procedure in spite of its obvious benefits.
Use of the Quadriceps tendon in ACL reconstruction surgery has generally remained the purview of high end specialists who perform the procedure by hand. However, as the evidence grows we believe the market is predisposed to adopt the Quadricep tendon solution.
We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.
Individuals over 18 years of age can invest.
Investing in startups and small businesses is inherently risky and standard company risk factors such as execution and strategy risk are often magnified at the early stages of a company. In the event that a company goes out of business, your ownership interest could lose all value. Furthermore, private investments in startup companies are illiquid instruments that typically take up to five and seven years (if ever) before an exit via acquisition, IPO, etc.
Quadvantage Technology, Inc. is a privately held company, and its shares are not traded on a public stock exchange. As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically receive a return on your investment under the following two scenarios: The company gets acquired by another company. The company goes public (makes an initial public offering on the NASDAQ, NYSE, or another exchange). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on the exchange. It can take 5-7 years (or longer) to see a distribution or trading, as it takes years to build companies. In many cases, there will not be any return as a result of business failure. Investments in private placements and start-up investments in particular are speculative and involve a high degree of risk, and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investments tend to be in earlier stages of development, and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Additionally, investors on Regulation CF offerings will receive securities that are subject to holding period requirements. The most sensible investment strategy for start-up investing may include a balanced portfolio of different start-ups. Start-ups should only be part of your overall investment portfolio. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest.
Shares sold via Regulation Crowdfunding offerings have a one-year lock up period before those shares can be sold under certain conditions.
- to the company that issued the securities; - to an accredited investor; - to a family member (defined as a child, stepchild, grandchild, parent, stepparent, grandparent, spouse or spousal equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships.); - in connection with your death or divorce or other similar circumstance;
If a company does not reach their minimum funding goal, all funds will be returned to the investors after the closing of their offering.
All available financial information can be found on the offering pages for the company’s Regulation Crowdfunding offering.
You may cancel your investment at any time, for any reason until 48 hours prior to a closing occurring. If you have already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email investors@quadvantage.com